Telia

MEDTECHS’ COMEBACK CONFIRMED

06/11/26 -"In early September 2026, we suggested that the 5 lean years for MedTechs performance had maybe reached an end. Bingo. The following chart confirms the better momentum for that specialist universe. ..."

PDF page sample
Pages
59
Language
English
Published on
06/11/26
Download
You may also be interested by these reports :
06/11/26
SES delivered a strong Q3 2026, with like-for-like revenue increasing 4.2% y/y and adjusted EBITDA rising 18.6%, supported by a recovery in Media, ...
06/11/26
Two years ago, in September 2024, Telia (SELL; -7% DOWNSIDE) announced a new restructuring plan, incurring charges in its last quarter and killing a ...
05/11/26
Q2 revenue showed an initial inflection in the consumer segment, rising 4% yoy after a flat Q1. EBITDA growth of 3% also reflects the clear benefits ...
05/11/26
Deutsche Telekom’s Q3 performance in its German and European segments was in line with expectations. TMUS released its Q3 results one week ago, with ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO